NEW YORK, Aug 1 –Corvas International has signed a multi-year subscription to Incyte’s LifeSeq Gold database, the companies said Wednesday.
Corvas said it would use the database for its cancer research activities. The San Diego-based company is currently researching serine proteases to determine their potential as solid tumor drug targets.
"We are integrating genome-based research with our expertise in serine protease therapeutics to expand the scope and potential proprietary position of our cancer programs," Randall Woods, CEO of Corvas, said in a statement.
"We believe access to new proteases afforded by Incyte's genomic database will facilitate our development of a leading position in the serine protease field," he said.
The LifeSeq Gold database offers information on expressed sequence tag and full-length gene sequences, mapping data, and public genomic sequence information.
Incyte of Palo Alto, Calif., did not disclose the financial terms of the non-exclusive deal.